Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Amplitude (AMPL) Reports Record Net New ARR Driven by Robust Enterprise Growth

Netgear (NTGR) Returns to Growth in 2025 Behind Strategic Enterprise Expansion

Baird Lowers Workday (WDAY) Price Target after Reduced 2027 Guidance

Pump.fun (PUMP) To Rise Higher? This Potential Bullish Pattern Formation Suggest So!

